AP Biosciences, Inc.’s Post

Did you know that bispecific antibodies are all the rage at the minute? 💉 Their ability to deliver targeted therapeutics to patients by simultaneously binding to two different antigens or epitopes makes them an extremely attractive proposition to drug developers. 🧬 This can be seen in the fact that there have been multiple deals recently made by big pharma and biotech companies to acquire bispecific antibody companies or assets. 🤝💰 Plus, several biotechs have recently launched specifically to develop these types of drugs. 🚀 Read our latest article to discover six bispecific antibody companies! 👇️ https://lnkd.in/duhSmFFE #bispecificantibodies #drugdevelopment #biotechinnovation #antibodytherapies #biotechstartups  #medicalbreakthroughs   Adaptin Bio, Inc. | Akeso Biopharma | AP Biosciences, Inc. | Candid Therapeutics | Summit Therapeutics, Inc. | Zenas BioPharma

While smart Biologics are making exciting progress🚨we shouldn’t discount the canonical/vanilla mAbs🍦. These still account for over 50% of the commercial R&D clinical pipelines 💪 and of the 16 Biologics approved by the FDA 🎉in 2024: 10 are mAbs🍦3 are bispecific🥂 https://lnkd.in/e88uen8y. This is a nice piece by Matthew Pillar on antibodies, related AI, CMC and formats: https://lnkd.in/efYd_Dfj. #innovation #precisionmedicine #pharmacology #biologics #antibodies #oncology #biotechnology #AI #CMC #BPD #scienceandtechnology #reflections

#Candid will partner with EpimAb Biotherapeutics, #Nona Biosciences and #Ab Studio to boost its pipeline of bispecific antibodies, the company announced in Dec. 16 releases.

𝗥𝗼𝘂𝗻𝗱𝘂𝗽 𝗼𝗳 𝗶𝗺𝗽𝗼𝗿𝘁𝗮𝗻𝘁 𝗮𝗻𝘁𝗶𝗯𝗼𝗱𝘆 #biotech 𝗱𝗲𝗮𝗹𝘀 𝘁𝗵𝗶𝘀 𝗺𝗼𝗻𝘁𝗵 👇 🤖 Xaira Therapeutics launches with $1B, focused on using artificial intelligence to improve antibody drug discovery 💸 Zenas BioPharma announces $200M upsized Series C for lead product candidate, obexelimab, a bifunctional monoclonal antibody 🌱 RevOpsis Therapeutics secures $16.5M seed funding to advance its next generation multispecific antibody platform, including tri-specific for nAMD 💰 GIBF invests $10M in Nectin Therapeutics to advance lead candidate NTX1088, an mAb against PVR, and ADC pipeline 💰 Surf Bio granted $1.6M by Bill & Melinda Gates Foundation to increase thermostability and deliverability of a monoclonal antibody in low- and middle-income countries 💵 Context Therapeutics, with lead candidate, CTIM-76 bispecific antibody, receives $100M private placement 💸 Memo Therapeutics AG raises additional CHF 45M Series C financing to expand Phase II anti-BK virus antibody 🤝 Ligand Pharmaceuticals and Agenus enter into $100M royalty financing agreement, including support for botensilimab, an anti-CTLA-4 immune activator antibody 💵 ADC Therapeutics, with lead candidate CD19-directed ADC Zynlonta (loncastuximab tesirine-lpyl), announces $105M underwritten offering 💵 Eledon Pharmaceuticals, Inc. receives oversubscribed $50M private placement for lead product tegoprubart, an anti-CD40L antibody 🤝 Merck and CytomX Therapeutics will collaborate on evaluation of CX-801 in combination with Keytruda (pembrolizumab) #Biointron #Antibodies #Immunotherapy #PharmaNews #DrugDevelopment #DrugDiscovery #Oncology #Innovation #Networking #Healthcare

6 FREE Webcasts: Antibody Engineering & Therapeutics Spring Digital Week taking place May 20 - 21, 2024 | Join hundreds of your antibody peers 👉 Find out more & secure your free pass here: https://lnkd.in/erFEvh-F From Molecule to Market: Simplifying the Characterization of Antibody-Drug Conjugates (ADCs) 🕘 May 20: 12pm EDT / 5pm BST / 6pm CEST Antibody-drug conjugates (ADCs) are among the fastest growing class of biologics and are developed as a combination of monoclonal antibodies (mAbs) and highly potent cytotoxic molecules (drugs). The antibody, in addition to its own biological specificity through its paratope, has the function of a targeted transporting tool of the drug to the targeted cell. The conjugated molecules or particles typically have cytotoxic activity and thus increase the efficiency of the antibody by an additional mechanism, leading to increased death of cells carrying the target antigen. Conjugation of these drugs to antibodies, however, increases structural complexity, which triggers the need for improved characterization methods. Common analytical technologies for characterization of ADCs, such as liquid chromatography, electrophoresis, and mass spectrometry, are useful in enabling the optimization of ADCs but need to be complemented with technologies that can add biophysical and functional information. This session will demonstrate the use of Octet® Bio-Layer Interferometry (BLI) platform in combination with the iQue® High-Throughput Screening (HTS) by Cytometry to characterize and compare the drug trastuzumab to the trastuzumab-containing reference medicinal products Kadcyla® and Enhertu®. Listeners will learn assay considerations for ADCs characterization and the need for complimentary techniques for selection of optimal drug candidates. 👥 Speaker: David Apiyo, Ph.D., Senior Manager, Application, Sartorius #AntibodyEngineering #Therapeutics #AntibodyDiscovery #AcceleratedDiscovery #DrugConjuates

In this featured article on Labiotech.eu, our CEO 何正宏Jeng Her dives deep into the future of #bispecific antibodies, a promising therapeutic approach that is transforming treatment possibilities for #cancer and other diseases. From discussing the science behind bispecifics to exploring the key challenges in drug discovery, he emphasizes how innovation is reshaping the landscape of antibody-based treatments. Explore how our cutting-edge R&D is contributing to this revolution in immuno-oncology therapy! #IO

📈𝘽𝙞𝙤𝙥𝙝𝙖𝙧𝙢𝙖 𝘽𝙪𝙡𝙡𝙚𝙩𝙞𝙣: 𝙎𝙩𝙖𝙮 𝘼𝙝𝙚𝙖𝙙 𝙬𝙞𝙩𝙝 𝙏𝙝𝙚𝙨𝙚 5 𝙍𝙚𝙖𝙙𝙨 📚 📌 Vincerx Pharma (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, announced that it has entered into a binding term sheet for a proposed merger with Oqory, Inc., a privately-held, clinical-stage company developing ADCs for the treatment of multiple oncology indications. 📌  Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, announced encouraging interim safety, pharmacokinetic (PK) and efficacy results from participants with chronic hepatitis B virus (HBV) infection in its ongoing Phase 1b study evaluating ABI-4334, an investigational next-generation capsid assembly modulator (CAM). 📌 Insilico Medicine announced a significant milestone in its drug discovery journey with the nomination of ISM1745 as a preclinical candidate targeted at treating cancers that have lost the MTAP gene. This groundbreaking research positions ISM1745 as a competitive player in the landscape of targeted cancer therapies, particularly due to its unique mechanism of action as a MTA cooperative PRMT5 inhibitor. The nomination of this compound underscores the relevance of generative artificial intelligence in modern drug development, as it was realized through the cutting-edge platform called Chemistry42, which combines various advanced generative models to facilitate the design of novel drug candidates. 📌 Nona Biosciences, a global biotechnology company providing a total solution from “Idea to IND” (I to ITM), announced that BeiGene has exercised its exclusive option to acquire global development, manufacturing, and commercialization rights for an antibody-drug conjugate (ADC) from DualityBio, a collaborator of Nona Biosciences. 📌  Stoke Therapeutics (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, announced alignment with global regulatory agencies on the design of the Company’s Phase 3 EMPEROR study of zorevunersen as potentially the first disease-modifying medicine for the treatment of Dravet syndrome. #biotechnews #biotech #biopharma #biopharmanews

Thoughts on this? >> Monoclonal Antibodies Are Paving the Way for Advanced Therapies - Genetic Engineering & Biotechnology News >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #pharmaceutical #competitivemarketing #healthcare #biotech

🔬 This week’s CDMO news: Samsung Biologics secured $668 Million new manufacturing deals in 2024. https://lnkd.in/g5N_KpdF SEKISUI Diagnostics completes £15.7M CDMO expansion in UK. https://lnkd.in/gj9tYQsq Affinia Therapeutics partners with Forge Biologics for cGMP manufacturing of gene therapies. https://lnkd.in/geDNp4AZ SyVento BioTech launches European mRNA manufacturing facility in Poland. https://lnkd.in/gJSVYV53 Nutcracker Therapeutics launches new CRDMO services for RNA drug developers. https://lnkd.in/gekE6D_G DINAMIQS opens new R&D laboratories in Zurich to support cell and gene therapies. https://lnkd.in/gfYGUxsV SpectronRx partners with Cellectar Biosciences, Inc. for cancer therapy iopofosine I 131. https://lnkd.in/gFZxJv_w WuXi Biologics enhances Leverkusen facility with new prefilled syringe line. https://lnkd.in/gc6iyS2J Meiji Seika Pharma and ARCALIS, Inc. partner to advance mRNA vaccine manufacturing. https://lnkd.in/ggTNigH2 Cellectar Biosciences, Inc. secures 10-Year Ac-225 supply agreement with NorthStar Medical Radioisotopes, LLC. https://lnkd.in/gr4Z6gYN GenScript’s ProBio licenses PD-1 molecule to LaNova Medicines. https://lnkd.in/gi7U9TNA WuXi AppTec wins EcoVadis silver medal for sustainability in 2024. https://lnkd.in/gGenVSTi C-Ray Therapeutics secures $100M in series A+ financing for radiopharmaceutical innovations. https://lnkd.in/gHqXCycR Ardena secures GMP approval for nanomedicine facility in Oss. https://lnkd.in/gyVpka6m Scorpius Holdings Inc. launches Scorpius Ventures to support biotech onshoring. https://lnkd.in/gY9E3hZD PCI Pharma Services partners with ChiRhoClin, Inc. to secure supply of critical diagnostic drug. https://lnkd.in/gycMFYvb Abzena expands GMP cell-based potency assays across UK and US facilities. https://lnkd.in/g4cEK4HY For the latest CDMO News, sign up to our newsletter: https://lnkd.in/gHxD3TEJ #CDMO #Pharma #ContractManufacturing

👉 Discover How Changing Host Cell to CHO can Enhance Biosimilar Drug Safety and Efficacy! The world of biotechnology knows how critical the selection of host cells is for the production of monoclonal antibody-based drugs. The gold standard in this context are CHO cells, but there are also known and used therapeutics based on other cell lines. The decision about host cell line impact on the qualitative characteristics of the obtained monoclonal antibody including its glycosylation profile, which directly affects the biological activity of the drug. 💊   When we develop a new therapeutic, we can choose a host cell line from solutions available on the market. But what if we want to develop a biosimilar drug? Do we have to choose exactly the same host cell line that is used to obtain the original monoclonal antibody?   🔸 Our team has published data showing that changing host cells does not necessarily exclude the biosimilarity of the obtained drug, and may even positively affect its safety without reducing its biological activity. Presented study shows, that IgG1 antibodies formed in CHO and Sp2/0 cell lines have no significantly different amounts of non-fucosylated species that are critical for biological activity of the antibody. What is also important, antibodies formed in the CHO expression system are characterized by lack of Gal-Gal structures, and the lower level of NGNA structures. This is very advantageous, considering the fact that Gal-Gal are potentially immunogenic structures, and NGNA forms promote the clearance of the antibody, thus leading to a decrease in drug efficacy. 🤝   📝 Edyta Bartusik-Czubek, Bartłomiej Czubek, Paulina Toboła, Karolina Lonkwic, Piotr Miłek, Olga Grzyb, Julita Balcerek, PhD, MBA, IPMA C, Tadeusz Pietrucha, SŁAWOMIR JAROS. The CHO cell line as a potentially safer host for cetuximab therapeutic antibody production than the Sp2/0 cell line. Int. J. Biotechnol. 2023; 14(4): 277-292. 👉 doi: https://lnkd.in/dVw7hyDJ #CHOcells #biotechnology #InternationalJournalOfBiotechnology #MabionExperts